Jefferies Group LLC Increases Indivior PLC (LON:INDV) Price Target to GBX 540
Indivior PLC (LON:INDV) had its target price boosted by Jefferies Group LLC from GBX 490 ($6.38) to GBX 540 ($7.03) in a research note issued on Friday. The firm presently has a “buy” rating on the specialty pharmaceutical company’s stock. Jefferies Group LLC’s price target indicates a potential upside of 34.13% from the stock’s previous close.
A number of other analysts have also recently weighed in on INDV. Royal Bank Of Canada reissued an “outperform” rating and issued a GBX 470 ($6.12) target price on shares of Indivior PLC in a research note on Thursday, August 3rd. Numis Securities Ltd reissued a “buy” rating and issued a GBX 490 ($6.38) target price on shares of Indivior PLC in a research note on Thursday, July 27th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a GBX 500 ($6.51) target price on shares of Indivior PLC in a research note on Thursday, May 4th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. Indivior PLC presently has an average rating of “Buy” and a consensus target price of GBX 455.83 ($5.94).
Indivior PLC (LON:INDV) opened at 400.30 on Friday. The firm’s market capitalization is GBX 2.89 billion. The firm has a 50-day moving average price of GBX 338.04 and a 200-day moving average price of GBX 331.31. Indivior PLC has a 52 week low of GBX 266.60 and a 52 week high of GBX 409.74.
COPYRIGHT VIOLATION WARNING: This news story was first reported by Daily Political and is owned by of Daily Political. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/08/11/jefferies-group-llc-increases-indivior-plc-lonindv-price-target-to-gbx-540.html.
Indivior PLC Company Profile
Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.
Receive News & Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related companies with MarketBeat.com's FREE daily email newsletter.